Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

NCT01700673 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

NCT00037596 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

NCT00004056 ·Status: COMPLETED ·Phase: PHASE1

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

NCT03070093 ·Status: APPROVED_FOR_MARKETING

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

NCT05457010 ·Status: RECRUITING ·Phase: PHASE1

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

NCT02067143 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT00053131 ·Status: COMPLETED ·Phase: PHASE2

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02728050 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

NCT00071006 ·Status: COMPLETED ·Phase: PHASE2

Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

NCT00006122 ·Status: COMPLETED ·Phase: PHASE2

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

NCT03746912 ·Status: NO_LONGER_AVAILABLE

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

NCT06630221 ·Status: RECRUITING ·Phase: PHASE2

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

NCT06552416 ·Status: RECRUITING ·Phase: PHASE1

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

NCT03146871 ·Status: TERMINATED ·Phase: PHASE2

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

NCT00798213 ·Status: TERMINATED ·Phase: PHASE2

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

NCT00005962 ·Status: COMPLETED ·Phase: PHASE2

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

NCT02421939 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

NCT02708641 ·Status: COMPLETED ·Phase: PHASE2

Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia

NCT00003255 ·Status: COMPLETED ·Phase: PHASE2

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

NCT00003673 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of G-CSF-Priming in Elderly AML Patients

NCT00199147 ·Status: UNKNOWN ·Phase: PHASE4

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00002805 ·Status: COMPLETED ·Phase: PHASE2

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

NCT04358393 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

NCT01656252 ·Status: TERMINATED ·Phase: PHASE1/PHASE2